

## HIV in children

Condition for which IVIg use is in exceptional circumstances only

### Specific Conditions

- HIV in children

### Level of Evidence

Evidence of probable benefit – more research needed (Category 2a)

The need for intravenous immunoglobulin (IVIg) in paediatric HIV has been substantially reduced with the advent of highly active antiretroviral therapy (HAART). A trial of therapy may, however, be considered in children with significant recurrent bacterial infections despite HAART.

**Refer to the current product information sheet for further information.**

**The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.**

### Bibliography

Orange, JS, Hossny, EM, Weiler, CR, et al 2006, 'Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology', *Journal of Allergy and Clinical Immunology*, vol. 117, no. 4, pp. S525–53.

*Generated on: 31 March 2019*